among
mani
medic
applic
system
biolog
contend
infecti
diseas
one
import
tractabl
target
take
view
complex
immun
system
inevit
consequ
evolut
complex
frustrat
reductionist
effort
develop
hostdirect
therapi
infect
howev
sinc
host
vari
wide
suscept
toler
infect
hostdirect
therapi
like
effect
alter
biolog
suscept
host
induc
respons
similar
host
surviv
therapi
exert
minim
select
pressur
organ
thu
greatli
decreas
probabl
pathogen
resist
develop
system
medicin
approach
infect
potenti
provid
new
solut
old
problem
identifi
host
trait
potenti
amen
therapeut
intervent
host
immun
factor
could
target
hostdirect
therapi
furthermor
undiscov
subgroup
differ
respons
treatment
almost
certain
exist
among
patient
present
lifethreaten
infect
sinc
popul
markedli
clinic
heterogen
major
drive
forc
behind
highthroughput
clinic
phenotyp
studi
aspir
subgroup
hitherto
opaqu
observ
may
observ
data
gener
new
technolog
subgroup
patient
unlik
staticseri
clinic
biolog
phenotyp
may
reveal
differ
trajectori
pathophysiolog
diseas
differ
therapeut
approach
requir
suggest
two
major
goal
system
biolog
infect
medicin
identifi
subgroup
patient
share
treatabl
featur
integr
highthroughput
data
clinic
vitro
sourc
order
predict
tractabl
therapeut
target
potenti
alter
diseas
trajectori
individu
patient
address
infect
largest
singl
caus
death
human
worldwid
mani
infecti
agent
provid
relev
vitro
model
system
amen
studi
highthroughput
techniqu
recapitul
key
event
diseas
pathogenesi
review
consid
system
biolog
approach
may
leverag
address
major
unmet
need
infect
medicin
centuri
aim
improv
outcom
patient
infect
clinic
practic
unabl
therapeut
modul
host
immun
respons
infect
larg
due
inevit
complex
despit
contend
hostdirect
therapi
high
probabl
success
sinc
alreadi
consider
innat
variat
host
respons
infecti
diseas
rang
extrem
suscept
complet
resist
toler
infecti
diseas
surviv
right
genet
challeng
make
diseas
surviv
patient
would
otherwis
succumb
system
medicin
approach
infect
potenti
combin
integr
relev
signal
clinic
genom
transcriptom
proteom
pathogen
biolog
data
draw
infer
diseas
pathogenesi
discuss
exampl
aspect
approach
appli
variou
infecti
diseas
suggest
futur
goal
applic
system
biolog
infect
medicin
year
discoveri
penicillin
drug
still
promin
weapon
antibacteri
armamentarium
broadli
concept
underli
therapeut
approach
attempt
erad
pathogen
patient
bodi
use
antimicrobi
drug
remain
effect
treatment
although
spectacularli
success
focu
pathogen
two
limit
firstli
death
frequent
occur
infecti
diseas
despit
effect
antimicrobi
therapi
alongsid
direct
effect
microbi
virul
factor
tissu
damag
also
caus
host
immun
respons
immunemedi
damag
lead
respiratori
cardiovascular
renal
failur
sepsi
continu
even
erad
pathogen
present
treatment
exist
modifi
deleteri
aspect
host
immun
respons
secondli
antimicrobi
resist
threaten
liber
pathogen
rang
solitari
weapon
unless
someth
chang
death
infect
predict
soar
overtak
malign
diseas
even
develop
countri
therapi
modul
host
respons
infect
would
theoret
advantag
addit
promot
surviv
presenc
effect
antimicrobi
hosttarget
therapi
may
exert
less
power
select
pressur
pathogen
may
difficult
pathogen
evolv
overcom
view
develop
therapi
wellsuit
applic
system
approach
inevit
complex
immun
system
human
immun
system
arguabl
complic
organ
system
bodi
encompass
numer
effector
interrel
feedback
loop
extens
redund
complex
unsurpris
consid
immun
system
evolv
face
microbi
virul
factor
directli
interfer
regulatori
effector
mechan
exampl
microbi
interfer
host
immun
mechan
numer
divers
exampl
one
first
innat
immun
mechan
encount
mani
pathogen
phagocytosi
serv
prime
adapt
respons
elimin
invad
pathogen
intracellular
kill
pathogen
yersinia
speci
group
facult
intracellular
pathogen
encod
type
three
secret
system
directli
inject
effector
protein
host
cell
cytoplasm
modul
cytoskeleton
prevent
phagocytosi
induc
apoptosi
immun
cell
block
mapk
nfkb
pathway
reduc
cytokin
product
anoth
bacterium
pseudomona
aeruginosa
secret
proteas
cleav
host
protein
corticosteroidbind
globulin
releas
corticosteroid
hormon
cortisol
site
initi
infect
incapacit
local
innat
immun
respons
even
rel
tini
genom
influenza
viru
encod
protein
nonessenti
replic
seem
dedic
interf
induct
action
host
antivir
interferon
respons
sequest
viral
dsrna
prevent
activ
signal
inhibit
protein
kinas
r
oasrnas
l
adapt
respons
mediat
b
lymphocyt
also
target
human
immunodefici
viru
encod
three
protein
downregul
cell
surfac
express
distinct
mechan
prevent
mhci
signal
activ
cytotox
tcell
respons
virusinfect
cell
prevent
bcell
mount
antibodi
respons
infect
staphylococcu
aureu
surfac
protein
bind
fcg
portion
antibodi
exampl
cover
mechan
pathogen
evolv
extens
interfer
host
immun
respons
anim
innat
immun
system
thought
evolv
million
year
start
ameba
abl
phagocytos
extern
materi
nutrit
adapt
immun
system
mammal
thought
arisen
million
year
ago
fish
sinc
initi
event
immun
system
host
speci
particip
genet
arm
race
evolv
alongsid
relentless
exposur
microbi
immun
interfer
strategi
innumer
pathogen
furthermor
immun
system
must
success
distinguish
self
nonself
antigen
deleteri
consequ
aris
ie
autoimmun
diseas
fail
requir
overcom
microbi
immun
interfer
strategi
whilst
preserv
recognit
selfantigen
provid
necessari
pressur
drive
human
immun
system
evolv
huge
complex
organ
system
context
inevit
complex
surpris
reductionist
approach
develop
hosttarget
therapi
infecti
diseas
larg
subgroup
within
popul
patient
distinguish
share
diseas
process
treatabl
trait
pathophysiolog
featur
looser
sens
biomark
group
biomark
featur
determin
whether
given
therapi
improv
given
patient
outcom
trait
may
present
mani
differ
clinic
syndrom
diseas
process
reason
expect
asyet
undiscov
therapeut
intervent
could
alter
host
immun
respons
promot
surviv
infer
simpl
fact
host
better
other
confront
pathogen
host
respons
infect
case
know
studi
heterogen
furthermor
much
variat
herit
conclud
host
factor
exist
promot
surviv
specif
infect
must
vari
individu
henc
possibl
identifi
utilis
factor
therapeut
alter
biolog
suscept
host
induc
respons
similar
host
surviv
scale
challeng
find
target
hard
imagin
solut
found
without
power
system
approach
conceptu
could
involv
promot
resist
suppress
pathogen
replic
toler
prevent
damag
associ
immun
respons
pathogen
infect
pathogen
although
theoret
attract
tool
limit
damag
host
induc
toler
without
potenti
danger
sustain
high
pathogen
load
could
facilit
transmiss
iatrogen
supershedd
perhap
worryingli
emerg
zoonot
infect
provid
time
requir
select
mutant
better
host
adapt
due
reliabl
broad
act
antiinflammatori
effect
corticosteroid
repres
intuit
attract
strategi
reduc
inflamm
infect
inde
surviv
benefit
demonstr
small
number
uncommon
infect
bacteri
mening
tubercul
mening
pericard
hypoxaem
pneumocysti
jiroveci
pneumonia
contrast
uncertainti
safeti
benefit
infect
eg
rsv
bronchiol
clear
evid
harm
other
viral
hepat
cerebr
malaria
influenza
viru
sar
coronaviru
hivassoci
cryptococc
mening
specif
hostdirect
therapi
recombin
human
activ
protein
c
rhapc
licens
treatment
sever
sepsi
base
result
singl
clinic
trial
rhapc
antiinflammatori
antithrombot
properti
circul
level
low
patient
sepsi
sadli
subsequ
trial
overlap
patient
group
show
trend
toward
increas
mortal
third
trial
mandat
regulatori
author
detect
mortal
benefit
drug
quickli
withdrawn
market
neg
trial
result
sepsi
necessarili
conclus
heterogen
host
respons
divers
rang
microb
involv
mean
amongst
patient
sepsi
unrealist
broad
syndrom
like
numer
biologicallydiffer
subgroup
distinct
immun
respons
importantli
differ
risk
benefit
balanc
given
therapi
corticosteroid
exampl
may
save
patient
harm
other
current
understand
infect
allow
clinic
differenti
subgroup
potenti
benefici
therapi
may
fals
reject
clinic
trial
believ
major
output
system
approach
infect
elucid
previous
hidden
therapeuticallyimport
subgroup
patient
share
treatabl
trait
ie
respons
therapi
discuss
two
central
problem
infect
medicin
firstli
develop
therapi
modul
host
immun
respons
imped
inevit
complex
human
immun
system
secondli
rang
degre
characteris
clinic
syndrom
medicin
constrain
rang
observ
avail
like
fail
identifi
subgroup
patient
treatabl
trait
due
pauciti
relev
observ
promis
system
approach
infect
medicin
new
technolog
may
provid
solut
old
problem
largescal
biolog
dataset
increas
rang
highthroughput
technolog
becom
avail
includ
limit
highresolut
transcript
profil
mass
spectrometrybas
proteom
metabolom
genomescal
knockout
screen
whole
genom
sequencinggenomewid
associ
studi
modal
could
provid
new
biolog
import
observ
previous
observ
patient
like
observ
directli
relev
clinic
manag
e
challeng
identifi
one
matter
three
broad
categori
clinic
util
new
data
sourc
infect
medicin
identifi
treatabl
trait
therapeuticallyrelev
subgroup
identifi
new
therapeut
target
immun
respons
improv
prognost
valu
prognost
current
clinic
practic
view
limit
rang
therapeut
option
put
simpli
use
predict
futur
capac
chang
particularli
case
acut
immedi
lifethreaten
infect
rang
therapeut
option
limit
regardless
degre
certainti
attach
prognosi
therefor
suggest
first
two
applic
prioritis
contrast
identif
syndrom
collect
clinic
observ
tend
occur
patient
suffer
diseas
primari
mechan
progress
understand
human
diseas
sinc
long
time
hippocr
find
syndrom
first
step
toward
identifi
common
biolog
process
defin
diseas
ultim
identifi
effect
treatment
hope
applic
system
technolog
help
us
defin
treatabl
trait
infect
thu
provid
start
point
new
therapeut
intervent
figur
importantli
system
model
diseas
process
need
predict
everi
transcript
metabolit
massiv
multidimension
dataset
gener
new
technolog
primari
challeng
instead
identifi
compon
interhost
variat
amen
intervent
evid
diseas
process
chang
agusti
concept
treatabl
trait
term
coin
field
chronic
obstruct
lung
diseas
less
relev
comput
model
infect
could
therefor
includ
tradit
measur
pathogen
burden
evid
system
injuri
also
independ
compon
immun
respons
metabol
consequ
detect
use
highthroughput
technolog
behaviour
whole
system
may
impenetr
complex
compon
requir
predict
effect
intervent
may
far
simpler
trajectori
follow
patient
along
inform
set
vector
may
reveal
differ
group
patient
appear
clinic
similar
may
even
similar
outcom
differ
diseas
process
figur
map
flight
path
patient
diseas
anticip
summari
system
medicin
approach
infect
wide
rang
data
sourc
combin
use
variou
method
see
text
achiev
two
fundament
goalsclinicallyinform
phenotyp
patient
identif
therapeut
target
import
similar
differ
immun
respons
becom
appar
abil
identifi
group
patient
share
therapeuticallyrelev
similar
depend
measur
relev
biolog
signal
determin
classif
fundament
attract
highthroughput
technolog
e
probabl
measur
import
signal
greater
signal
measur
group
patient
diseas
endotyp
exist
alreadi
clear
therapeuticallyimport
subclassif
recent
discov
redefin
clinic
syndrom
asthma
ard
acut
mountain
sick
two
relat
autoimmun
condit
ancaassoci
vascul
aav
system
lupu
erythematosu
sle
tcell
gene
express
signatur
clearli
delin
two
distinct
endotyp
subsequ
work
elucid
immunolog
process
underli
subclassif
tcell
exhaust
process
associ
better
outcom
autoimmun
diseas
poor
clearanc
viral
infect
futur
may
possibl
manipul
pathway
therapeut
patient
aav
sle
prevent
relaps
opposit
direct
patient
chronic
viral
infect
promot
clearanc
even
bestcas
scenario
distanc
identif
tractabl
therapeut
target
success
exploit
clinic
practic
substanti
surpris
potenti
hostdirect
therapi
discov
highdimension
analyt
yet
proven
effect
clinic
trial
nonetheless
promis
lead
describ
exemplifi
differ
approach
integr
cell
cultur
anim
human
data
sequenti
identifi
host
antivir
factor
influenza
viru
use
comput
predict
transcript
data
proteom
genet
modifi
anim
studi
identifi
host
pathway
involv
pathogenesi
sar
coronaviru
virus
oblig
parasit
undergo
exclus
intracellular
replic
properti
make
ideal
studi
cell
cultur
host
factor
affect
viral
replic
expect
vivo
sirna
screen
use
genomewid
approach
identifi
host
factor
influenza
viru
infect
identifi
novel
host
antivir
factor
sirna
screen
confirmatori
vitro
work
includ
exogen
interferon
administr
stabl
express
demonstr
requir
effect
interferon
respons
inhibit
influenza
viru
replic
work
mice
undertaken
confirm
vivo
influenza
virusinfect
mice
suffer
fatal
viral
pneumonia
even
infect
lowpathogen
viru
genisismosa
group
identifi
singl
nucleotid
polymorph
hypothet
trajectori
two
group
patient
multidimension
space
line
indic
path
taken
singl
patient
period
organ
failur
highlight
red
superfici
similar
group
patient
may
appear
clinic
indistinguish
differ
trajectori
ill
reveal
inform
vector
deriv
highthroughput
data
b
reason
expect
biolog
differ
diseas
process
underli
differ
respons
hostdirect
therapi
within
code
region
human
strongli
overrepres
patient
hospitalis
influenza
viru
infect
major
requir
invas
ventil
metaanalysi
genom
studi
influenza
viru
infect
confirm
associ
snp
increas
suscept
infect
human
work
underway
mani
group
investig
impact
ifitm
protein
antivir
defenc
view
gener
hosttarget
antivir
therapi
exampl
highlight
potenti
systemswid
approach
integr
crossvalid
result
variou
experiment
modal
highthroughput
screen
cell
cultur
follow
target
studi
mice
human
converg
largescal
data
onto
singl
critic
host
immun
factor
acut
lung
injuri
ali
progress
acut
respiratori
distress
syndrom
major
featur
pathophysiolog
sar
coronaviru
inde
respiratori
viru
infect
patholog
chang
mice
similar
human
doserespons
relationship
viral
inoculum
sever
ali
host
respons
viru
result
ali
poorli
understood
investig
host
respons
associ
sever
acut
lung
injuri
murin
model
sar
coronaviru
sarscov
infect
transcriptom
profil
mice
infect
lethal
subleth
dose
viru
compar
correl
patholog
data
multipl
time
point
subject
bioinformat
network
analysi
modul
gene
involv
cell
adhes
extracellular
matrix
remodel
wound
heal
significantli
upregul
lethal
infect
model
compon
urokinas
pathway
found
enrich
differenti
regul
massspectrometri
proteom
analysi
use
explor
transcript
data
demonstr
sarscov
infect
result
increas
express
fibrin
b
g
chain
factor
viii
cytokeratin
compon
hyalin
membran
reduc
express
surfact
protein
lung
data
consist
histolog
postmortem
find
sarscov
infect
human
extens
fibrin
exud
extens
hyalin
membran
format
alveolar
collaps
observ
part
urokinas
pathway
contribut
ecm
remodel
confirm
find
transcript
proteom
studi
knockout
mice
infect
sarscov
found
wors
outcom
compar
wild
type
mice
systemsbas
approach
sarscov
sequenti
appli
transcript
proteom
genet
modif
techniqu
demonstr
urokinas
pathway
contribut
ali
thu
identifi
target
futur
experiment
medicin
work
determin
therapeut
alter
benefit
host
exampl
give
us
confid
expect
progress
along
similar
line
potenti
system
medicin
approach
becom
wide
appreci
expertis
comput
methodolog
grow
cost
gener
relev
data
fall
physician
long
made
progress
recognis
pattern
similar
observ
group
patient
determin
biolog
featur
diseas
amen
therapi
chang
unpreced
rate
advanc
new
resourc
tool
tackl
ancient
problem
diagnosi
therapi
infecti
diseas
respons
ensur
similar
acceler
clinic
progress
sorensen
ti
nielsen
gg
andersen
pk
teasdal
tw
genet
environment
influenc
prematur
death
adult
adopte
n
engl
j
med
prospect
cohort
studi
adopte
demonstr
genet
background
contribut
rel
risk
death
due
infect
ie
biolog
parent
also
die
infect
death
due
cancer
vascular
diseas
natur
caus
thu
affirm
suscept
infect
strongli
herit
trait
